Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine

NCT05205746 is registered in ClinicalTrials.gov with Laboratorio Avi-Mex, S.A. de C.V. as lead sponsor.

NCT NCT05205746
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05205746 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine
Lead sponsor
Laboratorio Avi-Mex, S.A. de C.V.
Phase
Phase 2
Overall status
Completed
Start date
November 23, 2021
Completion date
July 24, 2023
Enrollment
158 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

sars cov 2 infection